ITP

Data Usability Takes Root with Release of Validator Tool

Retrieved on: 
Friday, March 8, 2024

VIENNA, Va., March 08, 2024 (GLOBE NEWSWIRE) -- The Sequoia Project, a non-profit and trusted advocate for nationwide health IT interoperability, in collaboration with the American Health Information Management Association (AHIMA), today unveiled a data usability validator tool for health information exchanged in the United States.

Key Points: 
  • As part of the Data Usability Taking Root movement, any organization that pledges to adopt The Sequoia Project Data Usability Implementation Guide Version 1 is eligible to subscribe to the first-of-its-kind data usability validator testing tool to improve data usability and quality and testing services.
  • “The groundswell of support for the Data Usability Taking Root movement has been inspiring,” said Mariann Yeager, chief executive officer of The Sequoia Project.
  • Focused on advancing real-world improvements, these pioneering organizations are guiding the creation of a Data Usability Scorecard, Data Usability Implementation Guide Version 1 Compliance Readiness Checklist, Data Usability Implementation Guide Version 2, HL7 Virtual C-CDA Implementation-A-Thon tracks, and a new data usability validator.
  • The data usability validator tests conformance to the Data Usability Implementation Guide Version 1 and is a new module within the best-in-class Interoperability Testing Platform (ITP).

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Retrieved on: 
Wednesday, February 28, 2024

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call and webcasts today at 7:30 a.m. EST / 12:30 p.m. GMT / 8:30 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, February 29, 2024.

Key Points: 
  • HUTCHMED is committed to progressively embedding sustainability into all aspects of our operations and creating long-term value for our stakeholders.
  • The 2023 Sustainability Report will be published alongside our 2023 Annual Report in April 2024 and will include further information on HUTCHMED sustainability initiatives and their performance.
  • Net Income attributable to HUTCHMED for 2023 was $100.8 million compared to Net Loss attributable to HUTCHMED of $360.8 million in 2022.
  • The net income attributable to HUTCHMED in 2023 was $0.12 per ordinary share / $0.59 per ADS49, compared to net loss attributable to HUTCHMED of $0.43 per ordinary share / $2.13 per ADS in 2022.

Knight Therapeutics Announces Regulatory Submission of Fostamatinib in Brazil

Retrieved on: 
Wednesday, February 21, 2024

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.

Key Points: 
  • MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian health regulatory agency, for fostamatinib for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
  • Knight has previously submitted marketing authorization applications for fostamatinib in Colombia and Mexico.
  • “This submission of fostamatinib demonstrates Knight’s continued execution of our strategy of leveraging our solid platform and expertise to bring innovative therapies for important unmet healthcare needs in Latin America,” said Samira Sakhia, President and Chief Executive Officer of Knight Therapeutics Inc.
    On May 24, 2022, Knight announced that it entered into an agreement with Rigel Pharmaceuticals, Inc. for the exclusive rights to commercialize fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in Latin America.
  • Fostamatinib is commercially available in the United States under the brand name TAVALISSE® and in Europe under the brand name TAVLESSE® for the treatment of adult chronic ITP.

Digicel goes live with the BroadForward Diameter Router

Retrieved on: 
Wednesday, February 14, 2024

AMERSFOORT, The Netherlands, Feb. 13, 2024 /PRNewswire/ -- Digital Operator Digicel today announced it now has gone live with the BroadForward Diameter Routing Agent (DRA). The BroadForward DRA has replaced the legacy DRA systems while the BroadForward STP earlier replaced the IP Transfer Point (ITP) systems that were in use at 26 of Digicel's markets in the Caribbean and Central America. At the heart of the Digicel network, the BroadForward DRA provides intelligent routing and interworking of Diameter signaling traffic between multi-vendor network nodes.

Key Points: 
  • Digicel has deployed both the BroadForward STP and DRA, enabling 3G and 4G routing from a common converged signaling solution , capable of also carrying future 5G signaling traffic
    AMERSFOORT, The Netherlands, Feb. 13, 2024 /PRNewswire/ -- Digital Operator Digicel today announced it now has gone live with the BroadForward Diameter Routing Agent (DRA).
  • The BroadForward DRA has replaced the legacy DRA systems while the BroadForward STP earlier replaced the IP Transfer Point (ITP) systems that were in use at 26 of Digicel's markets in the Caribbean and Central America.
  • At the heart of the Digicel network, the BroadForward DRA provides intelligent routing and interworking of Diameter signaling traffic between multi-vendor network nodes.
  • Each deployed product therefore can call upon on-board support for protocols such as Diameter, SS7, SIP, ENUM, RADIUS, and HTTP/2.

Digicel goes live with the BroadForward Diameter Router

Retrieved on: 
Wednesday, February 14, 2024

AMERSFOORT, The Netherlands, Feb. 13, 2024 /PRNewswire/ -- Digital Operator Digicel today announced it now has gone live with the BroadForward Diameter Routing Agent (DRA). The BroadForward DRA has replaced the legacy DRA systems while the BroadForward STP earlier replaced the IP Transfer Point (ITP) systems that were in use at 26 of Digicel's markets in the Caribbean and Central America. At the heart of the Digicel network, the BroadForward DRA provides intelligent routing and interworking of Diameter signaling traffic between multi-vendor network nodes.

Key Points: 
  • Digicel has deployed both the BroadForward STP and DRA, enabling 3G and 4G routing from a common converged signaling solution , capable of also carrying future 5G signaling traffic
    AMERSFOORT, The Netherlands, Feb. 13, 2024 /PRNewswire/ -- Digital Operator Digicel today announced it now has gone live with the BroadForward Diameter Routing Agent (DRA).
  • The BroadForward DRA has replaced the legacy DRA systems while the BroadForward STP earlier replaced the IP Transfer Point (ITP) systems that were in use at 26 of Digicel's markets in the Caribbean and Central America.
  • At the heart of the Digicel network, the BroadForward DRA provides intelligent routing and interworking of Diameter signaling traffic between multi-vendor network nodes.
  • Each deployed product therefore can call upon on-board support for protocols such as Diameter, SS7, SIP, ENUM, RADIUS, and HTTP/2.

Management & Board changes

Retrieved on: 
Monday, February 5, 2024

Martin Angle, Chairman of the Company, said: "On behalf of the Board, I would like to thank Ian for his substantial contribution over the past four years.

Key Points: 
  • Martin Angle, Chairman of the Company, said: "On behalf of the Board, I would like to thank Ian for his substantial contribution over the past four years.
  • We wish Ian well for his deserved retirement and welcome Gabriel as the new CFO and Board member."
  • Kimberley Wood, who is currently the Senior independent Director, has advised the company she will be resigning from the Board.
  • Kimberley has recently accepted an executive appointment and is therefore required to reduce her Board commitments in order to meet the corporate governance guidance.

Genel Energy PLC: Trading and operations update

Retrieved on: 
Tuesday, January 30, 2024

Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update in advance of the Company's full-year 2023 results, which are scheduled for release on 26 March 2024.

Key Points: 
  • Genel Energy plc ('Genel' or 'the Company') issues the following trading and operations update in advance of the Company's full-year 2023 results, which are scheduled for release on 26 March 2024.
  • The information contained herein has not been audited and may be subject to further review.
  • We have cut all non-essential activity and significantly reduced spend, while developing a new source of income through domestic sales.
  • Genel’s claim is that the KRG’s termination of the PSCs was repudiatory and, as a consequence, is claiming substantial damages.

Ratnesh Kumar Jha Named GM, Institutional Language Products at ETS

Retrieved on: 
Wednesday, January 17, 2024

PRINCETON, N.J., Jan. 17, 2024 /PRNewswire/ -- ETS announced today that it has named Ratnesh Kumar Jha as its new GM, Institutional Language Products.

Key Points: 
  • PRINCETON, N.J., Jan. 17, 2024 /PRNewswire/ -- ETS announced today that it has named Ratnesh Kumar Jha as its new GM, Institutional Language Products.
  • Jha will work alongside Rohit Sharma, ETS Senior Vice President, Global Higher Education & Workskills on the global expansion of ETS's institutional language product portfolio, primarily the TOEIC® tests, TOEFL ITP® test and the TOEFL® Young Student Series.
  • In addition, he will work closely with Edusoft Ltd., an ETS subsidiary, to advance the growth of its language learning solutions business.
  • "Ratnesh's experience will be a tremendous asset to ETS and position these products for growth in a space where we see great potential."

Ratnesh Kumar Jha Named GM, Institutional Language Products at ETS

Retrieved on: 
Wednesday, January 17, 2024

PRINCETON, N.J., Jan. 17, 2024 /PRNewswire/ -- ETS announced today that it has named Ratnesh Kumar Jha as its new GM, Institutional Language Products.

Key Points: 
  • PRINCETON, N.J., Jan. 17, 2024 /PRNewswire/ -- ETS announced today that it has named Ratnesh Kumar Jha as its new GM, Institutional Language Products.
  • Jha will work alongside Rohit Sharma, ETS Senior Vice President, Global Higher Education & Workskills on the global expansion of ETS's institutional language product portfolio, primarily the TOEIC® tests, TOEFL ITP® test and the TOEFL® Young Student Series.
  • In addition, he will work closely with Edusoft Ltd., an ETS subsidiary, to advance the growth of its language learning solutions business.
  • "Ratnesh's experience will be a tremendous asset to ETS and position these products for growth in a space where we see great potential."

HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

Retrieved on: 
Thursday, January 11, 2024

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”). Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (“Syk”), being developed for the treatment of hematological malignancies and immune diseases.

Key Points: 
  • HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 10, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for sovleplenib for the treatment of adult patients with primary immune thrombocytopenia (“ITP”) has been accepted for review and granted priority review by the China National Medical Products Administration (“NMPA”).
  • Sovleplenib is a novel, selective, oral inhibitor targeting spleen tyrosine kinase (“Syk”), being developed for the treatment of hematological malignancies and immune diseases.
  • “Our submission includes data from the successful Phase III ESLIM-01 trial in China which demonstrated a durable response rate of sovleplenib for patients.
  • There is a significant need for new therapies in adult primary ITP which can significantly impair the quality of life for patients.”